Identification of Hepatic Fibrosis Using 4D-MRI

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To date, no specific treatment options exist for liver diseases, and there is a large global effort to find drugs that will halt liver disease progression in these patients.Liver fibrosis staging is essential as a diagnostic/prognostic measure and there is an increasing demand for accurate non-invasive liver stiffness measurement tools. This research project proposes a novel MR-based quantitative Liver Deformation Biomarker (qLDB) approach for non-invasive liver fibrosis assessment by using a new technique called 4D-MRI. 4D-MRI allows to overcome the limitations of currently used techniques. Hence, 4D-MRI may help to identify a novel biomarker for non-invasive staging of liver fibrosis , and therefore improve the final diagnosis of patients suffering from liver diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NMR-based Metabolic Profiling Identifies High Risk of MAFLD Patients With Advanced Fibrosis

NCT05734599

Metabolic Dysfunction-associated Fatty Liver Disease Metabolic Disease

UNKNOWN

Methods to Detect Liver Fibrosis

NCT03027700

Liver Fibroses Hepatic Steatosis

TERMINATED NA

Quantitative MRI Imaging in Diffuse Liver Diseases

NCT04626492

Fibrosis and Cirrhosis of Liver

UNKNOWN

68Ga-FAPI PET/CT in Liver Fibrosis Patients

NCT04533828

Liver Fibrosis Positron Emission Tomography

UNKNOWN EARLY_PHASE1

Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)

NCT01600105

Chronic Liver Disease

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic liver diseases represent a rising global health threat. A prolonged inflammatory state leads to progressive fibrosis that can result in liver cirrhosis associated with serious complications including loss of liver function or hepatocellular carcinoma development. A particularly strong increase in the prevalence, morbidity, and mortality occurs in fatty liver disease, such as non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease; (ALD).To date, no specific treatment options for these conditions exist, and there is a large global effort to find drugs that will halt liver disease progression in these patients. Liver fibrosis staging is essential as a diagnostic/prognostic measure and there is an increasing demand for accurate non-invasive liver stiffness measurement tools. This research project proposes a novel MR-based quantitative Liver Deformation Biomarker (qLDB) approach for non-invasive liver fibrosis assessment by using a new technique called 4D-MRI. This technique makes it possible to overcome limitations in currently used techniques, i.e. to capture the abdominal organs with high spatial resolution in 3-dimensions at a high frame rate of 2-3 Hz and enabled an entirely new insight into the human body. The final diagnosis (i.e., stage of fibrosis) is based on quantifying changes of the liver's mechanical properties by dynamic magnetic resonance (MR) measurements and comparing the liver's elastic deformation with healthy livers. This innovative methodology allows for the first time to quantitatively measure the elastic deformation of organs during free-breathing and for an extended period, since no harmful X-rays are required. The hypothesis of the study is that the mechanical changes a liver undergoes during liver disease progression are visible in 4D-MRI data sets as a reduced elasticity. This will be assessed using our 4D-MRI approach taking into account the liver's deformation induced by natural respiration and also cardiac pulsation. The primary objective of the study is to compare liver deformation, induced at different respiratory breath-hold positions, by respiratory motion, and cardiac pulsation, between healthy subjects and patients with histologically confirmed liver cirrhosis in order to find a novel biomarker for non-invasive staging of liver fibrosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

prospective, national, multi-center study

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Outcome Assessors

Statistician blinded for analysis

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

4D-MRI assessment for patients with liver diseases

patients with chronic liver diseases, acute liver inflammation or cardiac blood congestion to the liver will be assessed by MRI

Group Type EXPERIMENTAL

4D-MRI

Intervention Type DIAGNOSTIC_TEST

Novel MR-imaging (MRI) and postprocessing techniques, making it possible to capture breathing-induced abdominal motion, including liver motion, under free-breathing. For the first time, these techniques - called 4D-MRI - were able to capture the abdominal organs with high spatial resolution in 3-dimensions at a high frame rate of 2-3 Hz and enabled an entirely new insight into the human body.

4D-MRI assessment for healthy volunteers (control group)

healthy control subjects will be assessed by MRI

Group Type EXPERIMENTAL

4D-MRI

Intervention Type DIAGNOSTIC_TEST

Novel MR-imaging (MRI) and postprocessing techniques, making it possible to capture breathing-induced abdominal motion, including liver motion, under free-breathing. For the first time, these techniques - called 4D-MRI - were able to capture the abdominal organs with high spatial resolution in 3-dimensions at a high frame rate of 2-3 Hz and enabled an entirely new insight into the human body.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

4D-MRI

Novel MR-imaging (MRI) and postprocessing techniques, making it possible to capture breathing-induced abdominal motion, including liver motion, under free-breathing. For the first time, these techniques - called 4D-MRI - were able to capture the abdominal organs with high spatial resolution in 3-dimensions at a high frame rate of 2-3 Hz and enabled an entirely new insight into the human body.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age ≥ 18 years
* (a) Patients with histologically confirmed chronic liver disease, including NAFLD, ALD, viral hepatitis B and C, genetic (e.g. Wilson disease, hemochromatosis) or autoimmune liver disease
* (b) Patients with acute liver inflammation or cardiac blood congestion to the liver (as assessed by laboratory values, imaging findings and clinical history)
* ability to understand and consent to participate in this study

Exclusion Criteria

* Medical implant like cardiac pacemaker, pump, hip prosthesis
* Metallic objects in the body (e.g. splinters after an accident)
* Persons who have undergone brain or cardiac surgery
* Claustrophobia
* Body Weight \>140kg or as provided by the MR manufacturer
* Pregnant and lactating women
* (a) Active hepatocellular carcinoma (HCC) (remark: patients with a history of HCC and curative treatment can be included)
* (a) CHILD C cirrhosis
* (a) and (b) Patients with overt ascites (except if they respond to diuretic treatment and the ascites resolves)
* (c) Metabolic syndrome, BMI \>30 kg/m2
* (c) Acute or chronic liver disease
* Patients not willing or able to give a written informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes